No, we don’t need the password to associate the doctors and hospital. Once we register it, the password will be sent to the corresponding emails.
Our models don't differentiate between different types of dosing, so they can be viewed as outcomes for standard clinical practice. For instance, if MTD is more common in practice, the models may more closely reflect MTD.
Our flow cytometry, PARR, and Immunoprofile reports are emailed to you 3-4 days after receipt of your patient’s sample(s) at our lab. The Personalized Prediction Profile reports are emailed to you 6-7 days after receipt of your patient’s sample(s) at our lab.
No, we cannot run a drug sensitivity-only service. Please understand our AI-based drug response prediction models require flow cytometry and PARR parameters generated from our own instrumental setting. Even if the patient already has flow cytometry results from another laboratory, we need to run flow and PARR again anyway.
The more samples ImpriMed processes and the more clinical outcomes we receive from our customers, the more accurately our AI models are able to determine which drugs will work best for your patients. (Click to read more)
We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.